[Diabetic kidney disease (update 2023) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology].
Diabetische Nierenerkrankung (Update 2023) : Positionspapier der Österreichischen Diabetes Gesellschaft und der Österreichischen Gesellschaft für Nephrologie.
Chronic kidney disease
Diabetic kidney disease
Dialysis
Type 1 diabetes
Type 2 diabetes
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
21
12
2022
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Epidemiological investigations have shown that approximately 2-3% of all Austrians have diabetes mellitus with renal involvement, leaving 250,000 people in Austria affected. The risk of occurrence and progression of this disease can be attenuated by lifestyle interventions as well as optimization of blood pressure, blood glucose control and special drug classes. The present article represents the joint recommendations of the Austrian Diabetes Association and the Austrian Society of Nephrology for the diagnostic and treatment strategies of diabetic kidney disease. Epidemiologische Untersuchungen zeigen, dass etwa 2–3 % aller Österreicher*innen einen Diabetes mellitus mit Nierenbeteiligung aufweisen. Dies betrifft somit in Österreich etwa 250.000 Menschen. Das Risiko des Auftretens und Fortschreitens der diabetischen Nierenerkrankung kann durch Lebensstilinterventionen und Optimierung des arteriellen Blutdrucks, Blutzuckers und spezielle Medikamentenklassen vermindert werden. In diesem gemeinsamen Artikel der Österreichischen Gesellschaften für Nephrologie und Diabetologie werden die entsprechende Diagnostik und therapeutische Strategien bei diabetischer Nierenerkrankung vorgeschlagen.
Autres résumés
Type: Publisher
(ger)
Epidemiologische Untersuchungen zeigen, dass etwa 2–3 % aller Österreicher*innen einen Diabetes mellitus mit Nierenbeteiligung aufweisen. Dies betrifft somit in Österreich etwa 250.000 Menschen. Das Risiko des Auftretens und Fortschreitens der diabetischen Nierenerkrankung kann durch Lebensstilinterventionen und Optimierung des arteriellen Blutdrucks, Blutzuckers und spezielle Medikamentenklassen vermindert werden. In diesem gemeinsamen Artikel der Österreichischen Gesellschaften für Nephrologie und Diabetologie werden die entsprechende Diagnostik und therapeutische Strategien bei diabetischer Nierenerkrankung vorgeschlagen.
Identifiants
pubmed: 37101040
doi: 10.1007/s00508-022-02147-3
pii: 10.1007/s00508-022-02147-3
pmc: PMC10133372
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
182-194Informations de copyright
© 2023. The Author(s).
Références
Österreichische Gesellschaft für Nephrologie. Österreichisches Dialyse- und Transplantationsregister. Bd. 2022. 2022.
Kramar R. Austrian dialysis and transplant registry. 2016.
Prischl FC, et al. Diabetes-related end-stage renal disease in Austria 1965–2013. Nephrol Dial Transplant. 2015;30:1920–7.
pubmed: 25977308
doi: 10.1093/ndt/gfv113
Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.
pubmed: 24356592
doi: 10.2337/dc13-2112
de Boer IH, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2014;25:2342–50.
pubmed: 24925722
pmcid: 4178441
doi: 10.1681/ASN.2013091004
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.
doi: 10.1016/S0140-6736(99)12323-7
Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.
pubmed: 11565518
doi: 10.1056/NEJMoa011161
Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.
pubmed: 11565517
doi: 10.1056/NEJMoa011303
Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.
pubmed: 11565519
doi: 10.1056/NEJMoa011489
Geroldinger A, Hronsky HA, Endel F, Endel G, Oberbauer R, Heinze G. Estimation of the prevalence of chronic kidney disease in people with diabetes by combining information from multiple routine data collections. J R Stat Socc Ser A. 2019. https://doi.org/10.1111/rssa.12682 .
doi: 10.1111/rssa.12682
Zelnick LR, et al. Diabetes and CKD in the United States Population, 2009–2014. Clin J Am Soc Nephrol. 2017;12:1984–90.
pubmed: 29054846
pmcid: 5718269
doi: 10.2215/CJN.03700417
Adler AI. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32.
pubmed: 12472787
doi: 10.1046/j.1523-1755.2003.00712.x
Fox CS, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73.
pubmed: 23013602
pmcid: 3771350
doi: 10.1016/S0140-6736(12)61350-6
Kimmelstiel P, Kim OJ, Beres J. Studies on renal biopsy specimens, with the aid of the electron microscope. I. Glomeruli in diabetes. Am J Clin Pathol. 1962;38:270–9.
pubmed: 14456010
doi: 10.1093/ajcp/38.3.270
Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12:83–98.7.
pubmed: 19970254
pmcid: 1911022
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78.
pubmed: 6400670
doi: 10.2337/diab.32.2.S64
Mauer SM, et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74:1143–55.
pubmed: 6480821
pmcid: 425280
doi: 10.1172/JCI111523
Steinke JM, Mauer M, International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev. 2008;5(Suppl 4):958–63.
pubmed: 18806710
Auinger M, et al. Diabetic nephropathy—Update 2012. Wien Klin Wochenschr. 2012;124(Suppl 2):42–9.
pubmed: 23262747
doi: 10.1007/s00508-012-0262-6
Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–7.
pubmed: 12824208
doi: 10.1001/jama.289.24.3273
Retnakaran R, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes. 2006;55:1832–9.
pubmed: 16731850
doi: 10.2337/db05-1620
Rodriguez-Poncelas A, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 2013;14:46.
pubmed: 23433046
pmcid: 3598539
doi: 10.1186/1471-2369-14-46
Thomas MC, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32:1497–502.
pubmed: 19470839
pmcid: 2713618
doi: 10.2337/dc08-2186
Ismail-Beigi F, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30.
pubmed: 20594588
pmcid: 4123233
doi: 10.1016/S0140-6736(10)60576-4
Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38:954–62.
pubmed: 25998286
pmcid: 4439536
doi: 10.2337/dc15-0184
Looker HC, et al. Structural lesions on kidney biopsy in youth-onset and adult-onset type 2 diabetes. Diabetes Care. 2022;45:436–43.
pubmed: 35006272
pmcid: 8914414
doi: 10.2337/dc21-1688
Tervaert TW, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556–63.
pubmed: 20167701
doi: 10.1681/ASN.2010010010
de Boer IH, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022. https://doi.org/10.2337/dci22-0027 .
doi: 10.2337/dci22-0027
Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–70.
pubmed: 10075613
doi: 10.7326/0003-4819-130-6-199903160-00002
Levey AS, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–72.
pubmed: 17332152
doi: 10.1373/clinchem.2006.077180
Fu EL, et al. Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population. Nephrol Dial Transplant. 2022. https://doi.org/10.1093/ndt/gfac197 .
doi: 10.1093/ndt/gfac197
pmcid: 10064839
Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
pubmed: 19414839
pmcid: 2763564
doi: 10.7326/0003-4819-150-9-200905050-00006
Kalantar-Zadeh K, Amin AN. Toward more accurate detection and risk stratification of chronic kidney disease. JAMA. 2012;307:1976–7.
pubmed: 22570467
doi: 10.1001/jama.2012.4623
White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis. 2010;55:660–70.
pubmed: 20138414
doi: 10.1053/j.ajkd.2009.12.011
Carville S, Wonderling D, Stevens P. Early identification and management of chronic kidney disease in adults: Summary of updated NICE guidance. BMJ. 2014;349:g4507.
pubmed: 25059691
doi: 10.1136/bmj.g4507
American Diabetes Association. 10. Microvascular complications and foot care: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41:105–S18.
doi: 10.2337/dc18-S010
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1–S115.
doi: 10.1016/j.kint.2020.06.019
Bellizzi V, et al. No additional benefit of prescribing a very low-protein diet in patients with advanced chronic kidney disease under regular nephrology care: a pragmatic, randomized, controlled trial. Am J Clin Nutr. 2022;115:1404–17.
pubmed: 34967847
doi: 10.1093/ajcn/nqab417
Cappuccio FP, et al. Sodium and health: Old myths and a controversy based on denial. Curr Nutr Rep. 2022;11:172–84.
pubmed: 35165869
pmcid: 9174123
doi: 10.1007/s13668-021-00383-z
Ekinci EI, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34:703–9.
pubmed: 21289228
pmcid: 3041211
doi: 10.2337/dc10-1723
Thomas MC, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861–6.
pubmed: 21307382
pmcid: 3064042
doi: 10.2337/dc10-1722
Banerjee T, et al. Poor accordance to a DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension. Kidney Int. 2019;95:1433–42.
pubmed: 30975440
pmcid: 6602537
doi: 10.1016/j.kint.2018.12.027
Mozaffari H, Ajabshir S, Alizadeh S. Dietary approaches to stop hypertension and risk of chronic kidney disease: A systematic review and meta-analysis of observational studies. Clin Nutr. 2020;39:2035–44.
pubmed: 31669002
doi: 10.1016/j.clnu.2019.10.004
Tyson CC, et al. Short-term effects of the DASH diet in adults with moderate chronic kidney disease: a pilot feeding study. Clin Kidney J. 2016;9:592–8.
pubmed: 27478603
pmcid: 4957723
doi: 10.1093/ckj/sfw046
Yuzbashian E, Asghari G, Mirmiran P, Amouzegar-Bahambari P, Azizi F. Adherence to low-sodium dietary approaches to stop hypertension-style diet may decrease the risk of incident chronic kidney disease among high-risk patients: A secondary prevention in prospective cohort study. Nephrol Dial Transplant. 2018;33:1159–68.
pubmed: 29361057
doi: 10.1093/ndt/gfx352
Dunkler D, et al. Population-attributable fractions of modifiable lifestyle factors for CKD and mortality in individuals with type 2 diabetes: a cohort study. Am J Kidney Dis. 2016;68:29–40.
pubmed: 26830448
doi: 10.1053/j.ajkd.2015.12.019
Docherty NG, le Roux CW. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat Rev Nephrol. 2020;16:709–20.
pubmed: 32778788
doi: 10.1038/s41581-020-0323-4
American Diabetes Association. 7. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S65–S72.
doi: 10.2337/dc18-S007
Gansevoort RT, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.
pubmed: 23727170
doi: 10.1016/S0140-6736(13)60595-4
Tonelli M, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14.
pubmed: 22717317
doi: 10.1016/S0140-6736(12)60572-8
Tuttle KR, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64:510–33.
pubmed: 25257325
doi: 10.1053/j.ajkd.2014.08.001
Tonelli M, et al. Association between LDL‑C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24:979–86.
pubmed: 23687359
pmcid: 3665395
doi: 10.1681/ASN.2012080870
Ferro CJ, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14:727–49.
pubmed: 30361677
doi: 10.1038/s41581-018-0072-9
Palmer SC, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–75.
pubmed: 22910937
pmcid: 3955032
doi: 10.7326/0003-4819-157-4-201208210-00007
Su X, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67:881–92.
pubmed: 26905361
doi: 10.1053/j.ajkd.2016.01.016
Haynes R, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825–33.
pubmed: 24790178
pmcid: 4116066
doi: 10.1681/ASN.2013090965
Wanner C, Tonelli M, Kidney Disease. Improving global outcomes lipid guideline development work group, M. KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–9.
pubmed: 24552851
doi: 10.1038/ki.2014.31
Toth PP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93(6):1397–408.
pubmed: 29526502
doi: 10.1016/j.kint.2017.12.011
Fellstrom BC, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.
pubmed: 19332456
doi: 10.1056/NEJMoa0810177
Wanner C, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.
pubmed: 16034009
doi: 10.1056/NEJMoa043545
Margreiter C, et al. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type‑2 diabetes mellitus. Transplantation. 2013;95:1030–6.
pubmed: 23407544
doi: 10.1097/TP.0b013e3182861945
Zoungas S, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392–406.
pubmed: 25234206
doi: 10.1056/NEJMoa1407963
Prischl FC, Wanner C. Renal outcomes of antidiabetic treatment options for type 2 diabetes—A proposed MARE definition. Kidney Int Rep. 2018;3:1030–8.
pubmed: 30197969
pmcid: 6127417
doi: 10.1016/j.ekir.2018.04.008
Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:1801–2.
pubmed: 27806236
doi: 10.1056/NEJMoa1515920
Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
pubmed: 28605608
doi: 10.1056/NEJMoa1611925
Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.
pubmed: 30415602
doi: 10.1056/NEJMoa1812389
Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.
pubmed: 32970396
doi: 10.1056/NEJMoa2024816
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.
pubmed: 30990260
doi: 10.1056/NEJMoa1811744
EMPA-KIDNEY Collaborative Group, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2204233 .
doi: 10.1056/NEJMoa2204233
Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
pubmed: 27295427
pmcid: 4985288
doi: 10.1056/NEJMoa1603827
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.
pubmed: 27633186
doi: 10.1056/NEJMoa1607141
Gerstein HC, et al. Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131–8.
pubmed: 31189509
doi: 10.1016/S0140-6736(19)31150-X
Schernthaner G, Schernthaner GH. Current treatment of type 2 diabetes. Internist (Berl). 2012;53:1399–410.
pubmed: 23179598
doi: 10.1007/s00108-012-3203-6
Alsahli M, Gerich JE. Hypoglycemia in patients with diabetes and renal disease. J Clin Med. 2015;4:948–64.
pubmed: 26239457
pmcid: 4470208
doi: 10.3390/jcm4050948
Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359–71.
pubmed: 8743335
doi: 10.2165/00003088-199630050-00003
Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380–c3.
pubmed: 21325870
doi: 10.1159/000323739
Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton). 2010;15:412–8.
pubmed: 20609092
doi: 10.1111/j.1440-1797.2010.01328.x
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–75.
pubmed: 25536258
pmcid: 4427053
doi: 10.1001/jama.2014.15298
Lalau JD, et al. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41:547–53.
pubmed: 29305402
doi: 10.2337/dc17-2231
Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR 45 mL/min). Nephrol Dial Transplant. 2015;30(Suppl 2):ii1–142.
doi: 10.1093/ndt/gfv100
Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110:75–81.
pubmed: 26361859
doi: 10.1016/j.diabres.2015.07.002
Tayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10:1128–9. author reply 1129–1130.
pubmed: 18671799
doi: 10.1111/j.1463-1326.2008.00928.x
Charbonnel BH, et al. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399–405.
pubmed: 15787663
doi: 10.1111/j.1464-5491.2004.01426.x
Hanefeld M, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141–7.
pubmed: 14693980
doi: 10.2337/diacare.27.1.141
Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167–74.
pubmed: 15386821
doi: 10.1002/dmrr.478
Schernthaner G, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068–76.
pubmed: 15579760
doi: 10.1210/jc.2003-030861
de Boer IH, et al. Diabetes and hypertension: A position statement by the American Diabetes Association. Diabetes Care. 2017;40:1273–84.
pubmed: 28830958
doi: 10.2337/dci17-0026
Weber T, et al. Austrian consensus on high blood pressure 2019. Wien Klin Wochenschr. 2019;131:489–590.
pubmed: 31792659
doi: 10.1007/s00508-019-01565-0
Taler SJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62:201–13.
pubmed: 23684145
pmcid: 3929429
doi: 10.1053/j.ajkd.2013.03.018
Messerli FH, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884–93.
pubmed: 16785477
doi: 10.7326/0003-4819-144-12-200606200-00005
Peralta CA, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012;172:41–7.
pubmed: 22232147
pmcid: 3417125
doi: 10.1001/archinternmed.2011.619
Kovesdy CP, et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med. 2013;159:233–42.
pubmed: 24026256
pmcid: 4155539
doi: 10.7326/0003-4819-159-4-201308200-00004
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.
pubmed: 8413456
doi: 10.1056/NEJM199311113292004
Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438.
pubmed: 26868137
pmcid: 4772784
doi: 10.1136/bmj.i438
Fried LF, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.
pubmed: 24206457
doi: 10.1056/NEJMoa1303154
Parving HH, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.
pubmed: 23121378
doi: 10.1056/NEJMoa1208799
Mann JF, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.
pubmed: 18707986
doi: 10.1016/S0140-6736(08)61236-2
Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.
pubmed: 33264825
doi: 10.1056/NEJMoa2025845
Pitt B, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–63.
pubmed: 34449181
doi: 10.1056/NEJMoa2110956
Agarwal R, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474–84.
pubmed: 35023547
doi: 10.1093/eurheartj/ehab777